Pancreatitis acute adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 21,951 adverse event reports that record the MedDRA preferred term Pancreatitis acute. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 1,564 reports in the 12 months to June 2026 and 1,403 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 75 drug pages with 100 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Pancreatitis acute name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		340
Allopurinol	Xanthine oxidase inhibitor	102
Amlodipine	Calcium channel blocker	137
Amoxicillin	Penicillin-class antibacterial	104
Asparaginase		101
Aspirin	Nonsteroidal anti-inflammatory drug	129
Atorvastatin		319
Azathioprine	Purine antimetabolite	253
Bactrim	Dihydrofolate reductase inhibitor antibacterial	145
Benicar	Angiotensin 2 receptor blocker	102
Bevacizumab	Vascular endothelial growth factor inhibitor	102
Byetta	GLP-1 receptor agonist	703
Carboplatin	Platinum-based drug	175
Creon		150
Crestor	HMG-CoA reductase inhibitor	122
Cyclophosphamide	Alkylating drug	270
Cytarabine	Nucleoside metabolic inhibitor	166
Dexamethasone	Corticosteroid	378
Doxorubicin	Anthracycline topoisomerase inhibitor	102
Doxycycline	Tetracycline-class drug	243
Enbrel	Tumor necrosis factor blocker	112
Esomeprazole	Proton pump inhibitor	142
Ezetimibe	Dietary cholesterol absorption inhibitor	112
Fenofibrate	Peroxisome proliferator receptor alpha agonist	184
Fluorouracil	Nucleoside metabolic inhibitor	137
Furosemide	Loop diuretic	253
Gabapentin	Anti-epileptic agent	125
Humira		189
Hydrochlorothiazide	Thiazide diuretic	238
Ibuprofen	Nonsteroidal anti-inflammatory drug	260
Janumet	Biguanide	152
Januvia	Dipeptidyl peptidase 4 inhibitor	493
Jardiance	Sodium-Glucose cotransporter 2 inhibitor	109
Kardegic		122
Lansoprazole	Proton pump inhibitor	133
Lisinopril	Angiotensin converting enzyme inhibitor	198
Mercaptopurine	Nucleoside metabolic inhibitor	136
Mesalamine	Aminosalicylate	119
Metformin	Biguanide	514
Metformin hcl	Biguanide	135
Metformin hydrochloride	Biguanide	150
Methotrexate	Folate analog metabolic inhibitor	377
Methylprednisolone	Corticosteroid	160
Metronidazole	Nitroimidazole antimicrobial	156
Mirtazapine		109
Mounjaro	GLP-1 receptor agonist	256
Mycophenolate mofetil	Antimetabolite immunosuppressant	180
Olanzapine	Atypical antipsychotic	143
Omeprazole	Proton pump inhibitor	281
Oncaspar	Asparagine-specific enzyme	111
Oxaliplatin	Platinum-based drug	151
Ozempic	GLP-1 receptor agonist	242
Paclitaxel	Microtubule inhibitor	102
Pantoprazole	Proton pump inhibitor	172
Paracetamol		165
Pegaspargase	Asparagine-specific enzyme	102
Prednisolone	Corticosteroid	298
Prednisone	Corticosteroid	362
Quetiapine	Atypical antipsychotic	163
Ramipril	Angiotensin converting enzyme inhibitor	232
Remicade	Tumor necrosis factor blocker	152
Ribavirin	Nucleoside analog antiviral	118
Rituximab	CD20-directed cytolytic antibody	154
Rosuvastatin	HMG-CoA reductase inhibitor	100
Seroquel	Atypical antipsychotic	370
Sertraline	Serotonin reuptake inhibitor	110
Simvastatin	HMG-CoA reductase inhibitor	232
Tacrolimus	Calcineurin inhibitor immunosuppressant	263
Tramadol		118
Trulicity	GLP-1 receptor agonist	282
Valproic acid	Anti-epileptic agent	168
Victoza	GLP-1 receptor agonist	622
Vincristine		168
Vincristine sulfate	Vinca alkaloid	100
Zyprexa	Atypical antipsychotic	118

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 28 pharmacologic classes with 250 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Pancreatitis acute name, in order of name
Class	Reports with this term
Alkylating drug	356
Aminosalicylate	252
Angiotensin 2 receptor blocker	521
Angiotensin converting enzyme inhibitor	559
Anti-epileptic agent	573
Antimetabolite immunosuppressant	300
Atypical antipsychotic	1,182
Biguanide	965
Calcineurin inhibitor immunosuppressant	481
Corticosteroid	1,419
Dipeptidyl peptidase 4 inhibitor	700
Folate analog metabolic inhibitor	503
GLP-1 receptor agonist	2,489
HMG-CoA reductase inhibitor	698
Kinase inhibitor	763
Loop diuretic	305
Nonsteroidal anti-inflammatory drug	687
Nucleoside metabolic inhibitor	678
Opioid agonist	372
Platinum-based drug	425
Programmed death Receptor-1 blocking antibody	310
Proton pump inhibitor	863
Purine antimetabolite	285
Serotonin reuptake inhibitor	311
Sodium-Glucose cotransporter 2 inhibitor	385
Tetracycline-class drug	292
Thiazide diuretic	328
Tumor necrosis factor blocker	465

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Pancreatitis acute, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Pancreatitis acute
Age	Reports	Share
Under 2	32	0.1%
2 to 11	506	2.3%
12 to 17	649	3%
18 to 44	4,289	19.5%
45 to 64	6,490	29.6%
65 to 74	3,059	13.9%
75 and over	2,110	9.6%
Age not given	4,816	21.9%

Sex of the patient in the reports that record Pancreatitis acute
Sex	Reports	Share
Female	9,786	44.6%
Male	9,960	45.4%
Unknown or not given	2,205	10%

Age and sex are as the report gives them. 35.9% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Pancreatitis acute: adverse event reports that record this term. https://reportedreactions.com/reaction/pancreatitis-acute/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Pancreatitis acute mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page